NO20076036L - Nye oksadiazolderivater og deres medisinske anvendelse - Google Patents

Nye oksadiazolderivater og deres medisinske anvendelse

Info

Publication number
NO20076036L
NO20076036L NO20076036A NO20076036A NO20076036L NO 20076036 L NO20076036 L NO 20076036L NO 20076036 A NO20076036 A NO 20076036A NO 20076036 A NO20076036 A NO 20076036A NO 20076036 L NO20076036 L NO 20076036L
Authority
NO
Norway
Prior art keywords
diseases
disorders
oxadiazole derivatives
medical use
nervous system
Prior art date
Application number
NO20076036A
Other languages
English (en)
Norwegian (no)
Inventor
Gunnar M Olsen
Dan Peters
Bjarne H Dahl
Daniel B Timmermann
Susanne Jorgensen
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of NO20076036L publication Critical patent/NO20076036L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
NO20076036A 2005-04-26 2007-11-23 Nye oksadiazolderivater og deres medisinske anvendelse NO20076036L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67471105P 2005-04-26 2005-04-26
DKPA200500612 2005-04-26
PCT/EP2006/061773 WO2006114400A1 (en) 2005-04-26 2006-04-24 Novel oxadiazole derivatives and their medical use

Publications (1)

Publication Number Publication Date
NO20076036L true NO20076036L (no) 2007-11-23

Family

ID=36697471

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076036A NO20076036L (no) 2005-04-26 2007-11-23 Nye oksadiazolderivater og deres medisinske anvendelse

Country Status (12)

Country Link
US (2) US8017631B2 (de)
EP (1) EP1881979B1 (de)
JP (1) JP2008539195A (de)
KR (1) KR20080000622A (de)
AT (1) ATE477253T1 (de)
AU (1) AU2006239418A1 (de)
CA (1) CA2606087A1 (de)
IL (1) IL186360A0 (de)
MX (1) MX2007013263A (de)
NO (1) NO20076036L (de)
RU (1) RU2007139255A (de)
WO (1) WO2006114400A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790757B2 (en) 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
IL169855A (en) * 2005-07-25 2014-05-28 Elta Systems Ltd A system and method for locating a receiver location
CA2616377C (en) 2005-07-26 2014-04-01 David Alexander Learmonth Nitrocatechol derivatives as comt inhibitors
EP1845097A1 (de) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazolderivate als COMT Inihibitoren
EP2255848A3 (de) * 2006-09-04 2011-04-06 NeuroSearch AS Pharmazeutische Kombinationen von Nicotin Rezeptor Modulatoren und Agenzien zur Verbesserung der kognitiven Fähigkeiten
TWI408139B (zh) 2006-09-07 2013-09-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
AU2007292993B2 (en) 2006-09-07 2013-01-24 Idorsia Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
MX2009002234A (es) 2006-09-08 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-3-il como agentes inmunomoduladores.
MX2009002915A (es) 2006-09-21 2009-03-31 Actelion Pharmaceuticals Ltd Derivados de fenilo y su uso como inmunomoduladores.
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
EP2481410B1 (de) 2007-01-31 2016-07-13 BIAL - Portela & Ca., S.A. Catechol Derivate als COMT-Hemmer eingenommen mit einer spezifischen Dosierungsanleitung
NZ580454A (en) 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
EP2786993B1 (de) 2007-08-13 2017-11-15 Monsanto Technology LLC Zusammensetzungen und Verfahren zur Kontrolle von Nematoden
PT2195311E (pt) 2007-08-17 2011-05-25 Actelion Pharmaceuticals Ltd Derivados de piridina como moduladores do receptor s1p1/edg1
US20090170842A1 (en) * 2007-11-14 2009-07-02 University Of Kansas Brca1-based breast or ovarian cancer prevention agents and methods of use
US8703775B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
WO2010009775A1 (de) * 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
ES2455197T3 (es) 2007-12-07 2014-04-14 Abbvie Deutschland Gmbh & Co Kg Derivados de oxindol 5,6-disustituidos y el uso de los mismos para la preparación de un medicamento para el tratamiento de enfermedades dependientes de vasopresina
NZ586651A (en) * 2007-12-07 2012-06-29 Abbott Gmbh & Co Kg 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
KR20100095593A (ko) 2007-12-10 2010-08-31 액테리온 파마슈티칼 리미티드 Ｓ１ｐ１/ｅｄｇ１의 작동약으로서 티오펜 유도체
CN101959504A (zh) * 2008-02-28 2011-01-26 比艾尔-坡特拉有限公司 用于难溶性药物的药物组合物
JP5481395B2 (ja) 2008-03-07 2014-04-23 アクテリオン ファーマシューティカルズ リミテッド 新規なアミノメチルベンゼン誘導体
TW200942531A (en) 2008-03-17 2009-10-16 Bial Portela & Companhia S A Crystal forms of a nitrocatechol
US8383658B2 (en) 2008-06-04 2013-02-26 Abbott Laboratories Isoxazole based neuronal nicotinic receptor ligands and methods of use
JP2011522818A (ja) * 2008-06-06 2011-08-04 アボット・ラボラトリーズ 新規１，２，４オキサジアゾール化合物およびこれらの使用方法
CN102131797A (zh) * 2008-09-02 2011-07-20 神经研究公司 三唑衍生物和它们用作烟碱乙酰胆碱受体调节剂的用途
WO2010035915A1 (en) * 2008-09-25 2010-04-01 Green Cross Corporation Sulfur containing pyrazole-heterocycle derivatives as cannabinoid cb1 receptor antagonists
WO2010080757A2 (en) * 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
CN110194765A (zh) 2009-02-10 2019-09-03 孟山都技术有限公司 用于控制线虫的组合物和方法
WO2010106106A1 (en) * 2009-03-19 2010-09-23 Neurosearch A/S 2, 5-disubstituted tetrazole derivatives and their use as nicotinic acetylcholine receptor modulators
KR20210009441A (ko) 2009-04-01 2021-01-26 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
EP2435080A2 (de) 2009-05-29 2012-04-04 Abbott Laboratories Pharmazeutische zusammensetzungen zur schmerzbehandlung
WO2010151815A2 (en) 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
SI2454255T1 (sl) 2009-07-16 2014-01-31 Actelion Pharmaceuticals Ltd. Derivati piridin-4-ila kot agonisti s1p1/edg1
AU2011256866B2 (en) 2010-05-20 2014-05-22 Astrazeneca Ab New process for the preparation of aryl substituted olefinic amines
EP2648518A2 (de) 2010-12-10 2013-10-16 Basf Se Pyridazolverbindungen zur bekämpfung von wirbellosen schädlingen
KR101869120B1 (ko) 2011-01-19 2018-06-19 이도르시아 파마슈티컬스 리미티드 2-메톡시-피리딘-4-일 유도체
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
PT2791134T (pt) 2011-12-13 2019-12-18 BIAL PORTELA & Cª S A Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
UA118254C2 (uk) 2012-12-04 2018-12-26 Монсанто Текнолоджи Ллс Нематоцидні водні композиції концентрату суспензії
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
ES2770348T3 (es) 2015-05-20 2020-07-01 Idorsia Pharmaceuticals Ltd Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol
ES2971120T3 (es) 2016-02-01 2024-06-03 Sumitomo Chemical Co Composición de control de plagas y método de control de plagas
US10676467B2 (en) 2017-06-30 2020-06-09 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof
MX2020010792A (es) 2018-04-13 2020-10-28 Bayer Ag Combinaciones de ingredientes activos con propiedades insecticidas, fungicidas y acaricidas.
US20230114241A1 (en) * 2019-09-05 2023-04-13 Trevena, Inc. Methods of treating epilepsy using the same
WO2022200364A1 (en) 2021-03-25 2022-09-29 Syngenta Crop Protection Ag Insect, acarina and nematode pest control

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3211742A (en) * 1962-04-17 1965-10-12 Union Carbide Corp Process for preparing oxadiazoles
IL31990A (en) * 1968-04-26 1974-05-16 Chinoin Gyogyszer Es Vegyeszet Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same
US3574842A (en) * 1969-11-10 1971-04-13 American Cyanamid Co Compositions of 4-(1,2,4-oxadiazole-3 or 5-yl)pyridinium salts and method of lowering blood sugar levels with same
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
DE2709660A1 (de) * 1977-03-05 1978-09-07 Basf Ag Sulfonsaeuregruppenhaltige azofarbstoffe mit oxdiazolylresten
FR2451932A2 (fr) * 1979-03-20 1980-10-17 Ugine Kuhlmann Nouveaux derives du diphenyl-3,5 oxadiazole-1,2,4, leur procede de preparation et leur application a la synthese de matieres colorantes
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US6060473A (en) * 1993-04-01 2000-05-09 Ucb S.A. - Dtb 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands
US6130217A (en) * 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
KR20040004705A (ko) * 2001-06-08 2004-01-13 시토비아 인크. 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도
FR2832712B1 (fr) * 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
US7144876B2 (en) * 2002-12-18 2006-12-05 Cytovia, Inc. 3,5-Disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
WO2004110351A2 (en) * 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
JP2006528980A (ja) 2003-05-15 2006-12-28 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類
AU2004277947A1 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
CN1894225A (zh) 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯

Also Published As

Publication number Publication date
KR20080000622A (ko) 2008-01-02
JP2008539195A (ja) 2008-11-13
US8017631B2 (en) 2011-09-13
AU2006239418A1 (en) 2006-11-02
IL186360A0 (en) 2008-01-20
WO2006114400A1 (en) 2006-11-02
ATE477253T1 (de) 2010-08-15
RU2007139255A (ru) 2009-06-10
CA2606087A1 (en) 2006-11-02
EP1881979A1 (de) 2008-01-30
US20110294856A1 (en) 2011-12-01
EP1881979B1 (de) 2010-08-11
MX2007013263A (es) 2008-01-22
US20090312347A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
NO20076036L (no) Nye oksadiazolderivater og deres medisinske anvendelse
MX2010001135A (es) Nuevos derivados de 1,2,3-triazol, utiles como modulares de receptores de acetilcolina nicotinicos.
MX2009003892A (es) Compuestos de oxadiazol y tiadiazol y su uso como moduladores del receptor de acetilcolina nicotinico.
IS7742A (is) Nýjar kvínúklidín-afleiður og notkun þeirra
NO20085398L (no) Nye 1,4-diazabisyklo[3.2 2]nonyloksadiazolylderivater og deres medisinske anvendelse
DK1551835T3 (da) Hidtil ukendte 1,4-diazabicycloalkanderivater, deres fremstilling og anvendelse
DE60310548D1 (de) Diazabicyclische biarylderivate
ATE455114T1 (de) Enantiomerenreine chinuclidinyloxy-pyridazine und ihre verwendung als nikotin-acetylcholin- rezeptorliganden
ATE481407T1 (de) Neue diazabicyclische arylderivate und medizinische verwendung dafür
DK1562945T3 (da) Hidtil ukendte diazebicykliske biarylderivater
DK1713487T3 (da) Diazabicykliske aryl-derivater som kolinerge receptor-modulatorer
ATE493415T1 (de) Neue diazabizyklische arylderivate und medizinische verwendung dafür
ATE445618T1 (de) Neue diazabicyclische arylderivate
WO2006087306A3 (en) Diazabicyclic aryl derivatives and their use as cholinergic ligands at the nicotinic acetylcholine receptors
DK1406900T3 (da) Hidtil ukendte forbindelser, fremstilling og anvendelse deraf
DK1963323T3 (da) Hidtil ukendte diazabicykliske arylderivater og medicinsk anvendelse heraf
ATE437880T1 (de) Dimere azacyclische verbindungen und deren verwendung
DE60307102D1 (de) 3-substituierte chinuklidine und deren verwendung
WO2005111033A3 (en) Novel azabicyclic aryl derivatives
ATE401334T1 (de) Neue azacyclische ethinylderivate
UA99443C2 (ru) Соединения оксадиазола и тиадиазола и их применение в качестве модуляторов никотиновых рецепторов ацетилхолина
ATE460416T1 (de) Neuartige 1,4-diazabicycloä3.2.2ünonan-derivate und deren medizinische verwendung
MX2007003331A (es) Nuevos derivados de arilo diazabiciclico.
ATE478869T1 (de) Diazabicycloalkan-derivate und ihre medizinische verwendung
DE602006019561D1 (de) Diazabicyclische arylderivate und ihre verwendung als chinolinergische liganden an nikotin-acetylcholin-rezeptoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application